F
Fernando G. Zampieri
Researcher at University of Southern Denmark
Publications - 165
Citations - 5298
Fernando G. Zampieri is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Medicine & Intensive care unit. The author has an hindex of 27, co-authored 126 publications receiving 3271 citations. Previous affiliations of Fernando G. Zampieri include Federal University of São Paulo & Federal University of Ceará.
Papers
More filters
Journal ArticleDOI
Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial.
Bruno Martins Tomazini,Israel Silva Maia,Alexandre Biasi Cavalcanti,Otavio Berwanger,Regis Goulart Rosa,Viviane C Veiga,Alvaro Avezum,Renato D. Lopes,Flavia Regina Bueno,Maria Vitoria Aparecida Oliveira Silva,Franca Pellison Baldassare,Eduardo L. V. Costa,Ricardo Antonio Bonifácio Moura,Michele Ouriques Honorato,André Nathan Costa,Lucas P. Damiani,Thiago Lisboa,Leticia Kawano-Dourado,Fernando G. Zampieri,Guilherme B Olivato,Cassia Righy,Cristina Prata Amendola,Roberta Muriel Longo Roepke,Daniela H M Freitas,Daniel Neves Forte,Flávio Geraldo Resende Freitas,Caio C. Fernandes,Livia Maria Garcia Melro,Gedealvares F S Junior,Douglas Costa Morais,Stevin Zung,Flávia Ribeiro Machado,Luciano Cesar Pontes Azevedo,Coalition Covid Brazil Iii Investigators +33 more
TL;DR: Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days over 28 days.
Journal ArticleDOI
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19.
Alexandre Biasi Cavalcanti,Fernando G. Zampieri,Regis Goulart Rosa,Luciano Cesar Pontes Azevedo,Viviane C Veiga,Alvaro Avezum,Lucas P. Damiani,Aline Marcadenti,Leticia Kawano-Dourado,Thiago Lisboa,Debora L. M. Junqueira,Pedro Gabriel Melo de Barros e Silva,Lucas Tramujas,Erlon Oliveira de Abreu-Silva,Lígia Nasi Laranjeira,Aline T. Soares,Leandro S. Echenique,Adriano José Pereira,Flávio Geraldo Resende Freitas,Otavio Gebara,Vicente C.S. Dantas,Remo H.M. Furtado,Eveline P. Milan,Nicole A. Golin,Fábio F. Cardoso,Israel Silva Maia,Conrado R. Hoffmann Filho,Adrian P.M. Kormann,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ary Serpa-Neto,Maicon Falavigna,Renato D. Lopes,Flávia Ribeiro Machado,Otavio Berwanger +34 more
TL;DR: Among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care.
Journal ArticleDOI
C-reactive protein/albumin ratio predicts 90-day mortality of septic patients.
Otavio T. Ranzani,Fernando G. Zampieri,Daniel Neves Forte,Luciano Cesar Pontes Azevedo,Marcelo Park +4 more
TL;DR: Residual inflammation at ICU discharge assessed using theCRP/albumin ratio is an independent risk factor for mortality at 90 days in septic patients and the use of the CRP/ Albumin ratio as a long-term marker of prognosis provides more consistent results than standard CRP values alone.
Journal ArticleDOI
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
Viviane C Veiga,João Prats,Danielle Leão Cordeiro de Farias,Regis Goulart Rosa,Letícia K. Dourado,Fernando G. Zampieri,Flávia Ribeiro Machado,Renato D. Lopes,Otavio Berwanger,Luciano Cesar Pontes Azevedo,Alvaro Avezum,Thiago Lisboa,Salomón Soriano Ordinola Rojas,Juliana C Coelho,Rodrigo T Leite,Júlio César de Carvalho,Luis Eduardo Coelho Andrade,Alex Freire Sandes,Maria Carolina Pintao,Claudio G Castro,Sueli V Santos,Thiago Miranda Lopes de Almeida,André Nathan Costa,Otavio Gebara,Flávio Geraldo Rezende Freitas,Eduardo Souza Pacheco,David J B Machado,Josiane Martin,Fábio G Conceição,Suellen R R Siqueira,Lucas P. Damiani,Luciana M Ishihara,Daniel Schneider,Denise de Souza,Alexandre Biasi Cavalcanti,Phillip Scheinberg +35 more
TL;DR: Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.
Journal ArticleDOI
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial.
Remo H.M. Furtado,Otávio Berwanger,Henrique Andrade Rodrigues da Fonseca,Thiago Domingos Corrêa,Leonardo José Rolim Ferraz,Maura G Lapa,Fernando G. Zampieri,Viviane C Veiga,Luciano Cesar Pontes Azevedo,Regis Goulart Rosa,Renato D. Lopes,Alvaro Avezum,Airton Leonardo de Oliveira Manoel,Felipe Maia de Toledo Piza,Priscilla de Aquino Martins,Thiago Lisboa,Adriano José Pereira,Guilherme B Olivato,Vicente C.S. Dantas,Eveline P. Milan,Otavio Gebara,Roberto Bleuel Amazonas,Monalisa Fernanda Bocchi de Oliveira,Ronaldo V P Soares,Diogo D.F. Moia,Luciana P.A. Piano,Kleber Castilho,Roberta G.R.A.P. Momesso,Guilherme Schettino,Luiz Vicente Rizzo,Ary Serpa Neto,Ary Serpa Neto,Flávia Ribeiro Machado,Alexandre Biasi Cavalcanti +33 more
TL;DR: The findings do not support the routine use of azithromycin in combination with hydroxychloroquine in patients with severe COVID-19 and suggest that standard of care treatment alone did not improve clinical outcomes.